体重指数是成年急性髓系白血病患者的一个预后因素。
Body mass index is a prognostic factor in adult patients with acute myeloid leukemia.
作者信息
Ando Taiki, Yamazaki Etsuko, Ogusa Eriko, Ishii Yoshimi, Yamamoto Wataru, Motohashi Kenji, Tachibana Takayoshi, Hagihara Maki, Matsumoto Kenji, Tanaka Masatsugu, Hashimoto Chizuko, Koharazawa Hideyuki, Fujimaki Katsumichi, Taguchi Jun, Fujita Hiroyuki, Kanamori Heiwa, Fujisawa Shin, Nakajima Hideaki
机构信息
Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
出版信息
Int J Hematol. 2017 May;105(5):623-630. doi: 10.1007/s12185-017-2183-7. Epub 2017 Jan 21.
Body mass index (BMI), which represents the proportion of weight to height, is a controversial prognostic factor for acute myeloid leukemia (AML). We evaluated prognostic value of BMI in Japanese AML. The study included 369 adult patients with newly diagnosed AML who were administered either daunorubicin or idarubicin with cytarabine as induction chemotherapy. The patients were categorized into two groups according to their BMI: the NW group (BMI < 25.0 kg/m; normal and underweight) and OW group (BMI ≥ 25.0 kg/m; overweight and obese). We analyzed treatment efficacy and toxicity of induction chemotherapy, and survival outcomes in each group. Patients in the OW group showed a better complete remission rate than the NW group (86.1 versus 76.5%, P = 0.045), no early death (0.0 versus 4.1%, P = 0.042), and better overall survival (OS) at 3 years (62.2 versus 50.1%, P = 0.012). Multivariate analysis showed BMI is an independent prognostic factor for OS (hazard ratio 0.62, 95% confidence interval 0.42-0.92, P = 0.017). These results indicate the prognostic value of BMI in adult AML patients.
体重指数（BMI）代表体重与身高的比例，是急性髓系白血病（AML）一个存在争议的预后因素。我们评估了BMI在日本AML患者中的预后价值。该研究纳入了369例新诊断的成年AML患者，这些患者接受了柔红霉素或伊达比星联合阿糖胞苷作为诱导化疗。根据BMI将患者分为两组：NW组（BMI < 25.0 kg/m；正常体重和体重不足）和OW组（BMI≥25.0 kg/m；超重和肥胖）。我们分析了诱导化疗的治疗效果和毒性，以及每组的生存结果。OW组患者的完全缓解率高于NW组（86.1%对76.5%，P = 0.045），无早期死亡（0.0%对4.1%，P = 0.042），3年总生存率（OS）更高（62.2%对50.1%，P = 0.012）。多变量分析显示BMI是OS的独立预后因素（风险比0.62，95%置信区间0.42 - 0.92，P = 0.017）。这些结果表明了BMI在成年AML患者中的预后价值。
Zotero 插件